HR and breast carcinoma: The 4th European School of Oncology–European Society for Medical Oncology (ESO–ESMO) international consensus guidelines for advanced breast cancer recommend endocrine therapy (ET)-based regimens as the preferred first-line treatment option for women with HR+/HER− advanced breast cancer [8].